Impaired lung NK activity in the lung of Idiopathic Pulmonary Fibrosis patients

T. Cruz (Barcelona, Spain), A. Bondonese (Pittsburgh, United States of America), J. Sembrat (Pittsburgh, United States of America), T. Tabib (Pittsburgh, United States of America), W. Zhang (Pittsburgh, United States of America), N. Mitash (Pittsburgh, United States of America), D. Vignali (Pittsburgh, United States of America), A. Mora (Columbus, United States of America), R. Lafyatis (Pittsburgh, United States of America), M. Rojas (Columbus, United States of America)

Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis
Session: Genetics and translational aspects of idiopathic pulmonary fibrosis
Session type: Oral Presentation
Number: 4332

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Cruz (Barcelona, Spain), A. Bondonese (Pittsburgh, United States of America), J. Sembrat (Pittsburgh, United States of America), T. Tabib (Pittsburgh, United States of America), W. Zhang (Pittsburgh, United States of America), N. Mitash (Pittsburgh, United States of America), D. Vignali (Pittsburgh, United States of America), A. Mora (Columbus, United States of America), R. Lafyatis (Pittsburgh, United States of America), M. Rojas (Columbus, United States of America). Impaired lung NK activity in the lung of Idiopathic Pulmonary Fibrosis patients. 4332

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014


Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014


Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO
Source: International Congress 2014 – ILDs 6
Year: 2014


Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020

Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014


Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014

Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014

Lung 18F-FDG uptake correlates with lung function alteration in patients with IPF
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016

The role of CCR2+CD4+T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014

Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014


Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016


Measurement of alveolar nitric oxide in IPF patients and in healthy controls
Source: International Congress 2014 – ILDs 4
Year: 2014


Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014


Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014


Circulating monocytes from interstitial lung disease patients show an activated phenotype
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016

Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014

Abnormal proliferation and differentiation of c-kit+ lung stem cells in pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014


Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014